Abstract:The COVID-19 disease is caused by a new strain of the coronavirus family (SARS-CoV-2), and it has affected at present millions of people all over the world. The indispensable role of the main protease (Mpro) in viral replication and gene expression makes this enzyme an attractive drug target. Therefore, inhibition of SARS-CoV-2 Mpro as a proposition to halt virus ingression is being pursued by scientists globally. Here we carried out a study with two objectives: the first being to perform comparative protein sequence and 3D structural analysis to understand the effect of 12 point mutations on the active site. Among these, two mutations, viz., Ser46 and Phe134, were found to cause a significant change at the active sites of SARS-CoV-2. The Ser46 mutation present at the entrance of the S5 subpocket of SARS-CoV-2 increases the contribution of other two hydrophilic residues, while the Phe134 mutation, present in the catalytic cysteine loop, can cause an increase in catalytic efficiency of Mpro by facilitating fast proton transfer from the Cys145 to His41 residue. It was observed that active site remained conserved among Mpro of both SARS-CoVs, except at the entrance of the S5 subpocket, suggesting sustenance of substrate specificity. The second objective was to screen the inhibitory effects of three different data sets (natural products, coronaviruses main protease inhibitors, and FDA-approved drugs) using a structure-based virtual screening approach. A total of 73 hits had a combo score >2.0. Eight different structural scaffold classes were identified, such as one/two tetrahydropyran ring(s), dipeptide/tripeptide/oligopeptide, large (approximately 20 atoms) cyclic peptide, and miscellaneous. The screened hits showed key interactions with subpockets of the active site. Further, molecular dynamics studies of selected screened compounds confirmed their perfect fitting into the subpockets of the active site. This study suggests promising structures that can fit into the SARS-CoV-2 Mpro active site and also offers direction for further lead optimization and rational drug design.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jcim.0c00546?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jcim.0c00546</a>.Phylogenetic relationship of SARS-CoV-2 Mpro; superimposed cocrystallized and redocked ligand; protein thermodynamic stability information upon point mutations; list of top Mpro inhibitors with their structures, source and scaffold information; interaction fraction histogram obtained from MD simulations; protein-ligand contact timeline information; RMSF plot for protein in presence of different ligands; binding free energy plot; and analysis of impact of mutation on active site residues of Mpro (<a class="ext-link" href="/doi/suppl/10.1021/acs.jcim.0c00546/suppl_file/ci0c00546_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Multiple redox switches of the SARS-CoV-2 main protease in vitro provide opportunities for drug design

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design.

A Novel Y-Shaped, S-O-N-O-S-Bridged Crosslink between Three Residues C22, C44, and K61 Is a Redox Switch of the SARS-CoV-2 Main Protease

De novo Design of SARS-CoV-2 Main Protease Inhibitors

A Novel Y-Shaped, S-O-N-O-S-Bridged Cross-Link Between Three Residues C22, C44, and K61 is Frequently Observed in the SARS-CoV-2 Main Protease.

Room-temperature X-ray crystallography reveals the oxidation and reactivity of cysteine residues in SARS-CoV-2 3CL Mpro: insights into enzyme mechanism and drug design

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development

Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV-2 Main Protease and its Variants Displaying Potent Antiviral Activity

SARS-CoV-2 Mpro responds to oxidation by forming disulfide and NOS/SONOS bonds

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors

Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays

Structure-Based Virtual Screening to Discover Potential Lead Molecules for the SARS-CoV-2 Main Protease

Design of novel and highly selective SARS-CoV-2 main protease inhibitors

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors

Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance

De Novo Design of SARS-CoV-2 Main Protease Inhibitors with Characteristic Binding Modes

Potential covalent drugs targeting the main protease of the SARS-CoV-2 coronavirus

Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity

Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease

The S1′–S3′ Pocket of the SARS‐CoV‐2 Main Protease is Critical for Substrate Selectivity and Can Be Targeted with Covalent Inhibitors